You just read:

Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis

News provided by

Eli Lilly and Company

Jan 19, 2016, 08:00 ET